π£ VC round data is live. Check it out!
- Public Comps
- KalVista Pharmaceuticals
KalVista Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for KalVista Pharmaceuticals and similar public comparables like Youcare Pharmaceutical, Harrow, HBM Holdings, UroGen Pharma and more.
KalVista Pharmaceuticals Overview
About KalVista Pharmaceuticals
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Founded
2004
HQ

Employees
270
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialKalVista Pharmaceuticals Financials
KalVista Pharmaceuticals reported last 12-month revenue of $105M.
In the same LTM period, KalVista Pharmaceuticals generated $96M in gross profit and had net loss of ($88M).
Revenue (LTM)
KalVista Pharmaceuticals P&L
In the most recent fiscal year, KalVista Pharmaceuticals reported revenue of $49M and EBITDA of ($173M).
KalVista Pharmaceuticals is unprofitable as of last fiscal year, with EBITDA margin of (353%) and net margin of (223%).
Financial data powered by Morningstar, Inc.
KalVista Pharmaceuticals Stock Performance
KalVista Pharmaceuticals has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
KalVista Pharmaceuticals' stock price is $26.73.
KalVista Pharmaceuticals share price increased by 0.3% in the last 30 days, and by 126.5% in the last year.
KalVista Pharmaceuticals has an EPS (earnings per share) of $-2.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | 0.3% | 64.2% | 126.5% | $-2.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKalVista Pharmaceuticals Valuation Multiples
KalVista Pharmaceuticals trades at 12.1x EV/Revenue multiple, and (7.3x) EV/EBITDA.
EV / Revenue (LTM)
KalVista Pharmaceuticals Financial Valuation Multiples
As of May 9, 2026, KalVista Pharmaceuticals has market cap of $1B and EV of $1B.
KalVista Pharmaceuticals has a P/E ratio of (16.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified KalVista Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


KalVista Pharmaceuticals Margins & Growth Rates
KalVista Pharmaceuticals grew revenue by 323% but EBITDA decreased by 61% in the last fiscal year.
In the most recent fiscal year, KalVista Pharmaceuticals reported EBITDA margin of (353%) and net margin of (223%).
KalVista Pharmaceuticals Margins
KalVista Pharmaceuticals Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
KalVista Pharmaceuticals Operational KPIs
KalVista Pharmaceuticals' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.7M for the same period.
KalVista Pharmaceuticals' Rule of 40 is 95% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
KalVista Pharmaceuticals' Rule of X is 242% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
KalVista Pharmaceuticals Competitors
KalVista Pharmaceuticals competitors include Youcare Pharmaceutical, Harrow, HBM Holdings, UroGen Pharma, Maze Therapeutics, Jiangxi Fushine Pharma, Liaoning Chengda Biotech, Semnur Pharmaceuticals, EczacΔ±baΕΔ± Δ°laΓ§ and WAVE Life Sciences.
Most KalVista Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.6x | β | (1236.5x) | β | |||
| 5.9x | 5.3x | 25.9x | 23.1x | |||
| 6.9x | 6.0x | 11.1x | 10.8x | |||
| 13.5x | 9.1x | (11.9x) | (17.3x) | |||
| β | 253.4x | (8.0x) | (7.7x) | |||
| 8.9x | 6.8x | 65.5x | 23.8x | |||
| 3.5x | 3.6x | 13.8x | 15.7x | |||
| β | β | (8.7x) | β | |||
This data is available for Pro users. Sign up to see all KalVista Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||
KalVista Pharmaceuticals Funding History
Before going public, KalVista Pharmaceuticals raised $33M in total equity funding, across 1 round.
KalVista Pharmaceuticals Funding Rounds
KalVista Pharmaceuticals M&A Activity
KalVista Pharmaceuticals has acquired 1 company to date.
Last acquisition by KalVista Pharmaceuticals was on June 15th 2016. KalVista Pharmaceuticals acquired Carbylan Therapeutics for undisclosed valuation.
Latest Acquisitions by KalVista Pharmaceuticals
| Description | Carbylan Therapeutics is a Palo Alto-headquartered clinical-stage biopharmaceutical company developing combination therapies for underserved markets. Founded in 2004, it advances proprietary formulations targeting pain management and gastrointestinal disorders through late-stage trials in the United States. |
| HQ Country | |
| HQ City | San Francisco, CA |
| Deal Date | 15 Jun 2016 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all KalVista Pharmaceuticals acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout KalVista Pharmaceuticals
| When was KalVista Pharmaceuticals founded? | KalVista Pharmaceuticals was founded in 2004. |
| Where is KalVista Pharmaceuticals headquartered? | KalVista Pharmaceuticals is headquartered in United States. |
| How many employees does KalVista Pharmaceuticals have? | As of today, KalVista Pharmaceuticals has over 270 employees. |
| Who is the CEO of KalVista Pharmaceuticals? | KalVista Pharmaceuticals' CEO is Benjamin L. Palleiko. |
| Is KalVista Pharmaceuticals publicly listed? | Yes, KalVista Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of KalVista Pharmaceuticals? | KalVista Pharmaceuticals trades under KALV ticker. |
| When did KalVista Pharmaceuticals go public? | KalVista Pharmaceuticals went public in 2015. |
| Who are competitors of KalVista Pharmaceuticals? | KalVista Pharmaceuticals main competitors include Youcare Pharmaceutical, Harrow, HBM Holdings, UroGen Pharma, Maze Therapeutics, Jiangxi Fushine Pharma, Liaoning Chengda Biotech, Semnur Pharmaceuticals, EczacΔ±baΕΔ± Δ°laΓ§, WAVE Life Sciences. |
| What is the current market cap of KalVista Pharmaceuticals? | KalVista Pharmaceuticals' current market cap is $1B. |
| What is the current revenue of KalVista Pharmaceuticals? | KalVista Pharmaceuticals' last 12 months revenue is $105M. |
| What is the current revenue growth of KalVista Pharmaceuticals? | KalVista Pharmaceuticals revenue growth (NTM/LTM) is 131%. |
| What is the current EV/Revenue multiple of KalVista Pharmaceuticals? | Current revenue multiple of KalVista Pharmaceuticals is 12.1x. |
| Is KalVista Pharmaceuticals profitable? | No, KalVista Pharmaceuticals is not profitable. |
| What is the current net income of KalVista Pharmaceuticals? | KalVista Pharmaceuticals' last 12 months net income is ($88M). |
| How many companies KalVista Pharmaceuticals has acquired to date? | As of May 2026, KalVista Pharmaceuticals has acquired 1 company. |
| What was the largest acquisition by KalVista Pharmaceuticals? | None of the M&A deals KalVista Pharmaceuticals has completed have disclosed valuations. |
| What companies KalVista Pharmaceuticals acquired? | KalVista Pharmaceuticals acquired Carbylan Therapeutics. |
| In how many companies KalVista Pharmaceuticals has invested to date? | KalVista Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to KalVista Pharmaceuticals
Lists including KalVista Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
